Abstracts tagged "Collagen"

Abstract Number: 878 • 2013 ACR/ARHP Annual Meeting
Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen¹, Diana J. Leeming², Adam Platt³, Inger Byrjalsen⁴, Claus Christiansen⁵, Désirée van de Heijde⁶ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁶Department of Rheumatology, Leiden Univerisity, Leiden, Netherlands
Background/Purpose: As biological treatments for rheumatoid arthritis (RA) are only effective in a subpopulation of patients and the treatment can have serious side effects, there…
Abstract Number: 2501 • 2012 ACR/ARHP Annual Meeting
Mirorna Mir-150 Contributes to Chronic Kidney Injury in Lupus Nephritis by Increasing the Synthesis of Fibrotic Proteins Via Downregulation of SOCS1
Hua Zhou¹, Sarfaraz A. Hasni², Mayank Tandon³, Shyh-Ing Jang⁴, Howard A. Austin⁵, James E. Balow⁶, Ilias Alevizos³ and Gabor G. Illei³, ¹NIDCR/NIH, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Sjogren's Clinic, NIDCR/NIH, Bethesda, MD, ⁴Molecular Physiology and Therapeutics Branch, NIDCR/NIH, Bethesda, MD, ⁵Kidney Disease Section, NIDDK/NIH, Bethesda, MD, ⁶Clinical Director, NIDDK, NIDDK/NIH, Bethesda, MD
Background/Purpose: We have previously shown that renal expression of miR-150 correlates with chronicity index (CI) in lupus nephritis. Since fibrosis is a major histologic feature…
Abstract Number: 2306 • 2012 ACR/ARHP Annual Meeting
Intratracheal Instillation of Omniscan in an Adenine-Induced Model of Chronic Renal Failure: A New Model of Nephrogenic Systemic Fibrosis
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Nephrogenic Systemic Fibrosis (NSF), a generalized progressive fibrotic disorder, occurs in some patients with renal insufficiency exposed to various gadolinium based contrast agents (GdBCA). …
Abstract Number: 2286 • 2012 ACR/ARHP Annual Meeting
Dysregulated Discoidin Domain Receptor 2-Microrna 196a-Mediated Negative Feedback Against Excess Type I Collagen Expression in Scleroderma Dermal Fibroblasts
Katsunari Makino¹, Masatoshi Jinnin¹, Jun Aoi¹, Ikko Kajihara¹, Takamitsu Makino², Keisuke Sakai¹, Satoshi Fukushima¹, Yuji Inoue¹ and Hironobu Ihn², ¹Department of Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan, ²Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan
Background/Purpose: Systemic sclerosis (SSc) is characterized by the excess deposition of collagen in the skin, due to intrinsic transforming growth factor (TGF)-β activation. The discoidin…
Abstract Number: 1778 • 2012 ACR/ARHP Annual Meeting
Adenosine A2A Receptor (A_2AR) Activation Stimulates Increased Expression of Collagen-1 and Collagen-3 by Different Signaling Pathways in Normal Human Dermal Fibroblasts
Miguel Perez Aso¹ and Bruce N. Cronstein², ¹NYU Univ Medical Center, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Pathological fibrosis in the skin and other organs is the hallmark of scleroderma and other fibrosing diseases. Adenosine, acting at A2AR, plays a critical…
Abstract Number: 1518 • 2012 ACR/ARHP Annual Meeting
Damage-Associated Endogenous TLR4 Ligand Fibronectin-EDA Is Overexpressed in Scleroderma and Drives Persistent Fibrosis Via TLR4 and Inhibition of TLR4 Prevents and Reverses Experimental Dermal Fibrosis: Novel Target for Scleroderma Therapy
Swati Bhattacharyya¹, Zenshiro Tamaki², Wenxia Wang³, Paul Hoover⁴, Adam Booth⁵, Alyssa Dreffs⁶, Monique E. Hinchcliff⁷, Feng Fang⁸, Spiro Getsios⁴, Hang Yin⁹, Eric S. White⁶ and John Varga¹⁰, ¹Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²Medicine, Rheumatology, Northwestern Univ Med School, Chicago, IL, Chicago, IL, ³Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁵Ann Arbor, MI, ⁶Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁷Division of Rheumatology, Northwestern Univ Med School, Chicago, IL, ⁸Rheumatology Division, Northwestern University, Chicago, IL, ⁹University of Colorado at Boulder, Boulder, CO, ¹⁰Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Recent studies implicate innate immune signaling and Toll like receptor-4 (TLR4) in fibrogenesis. We hypothesized that injury in scleroderma leads to tissue accumulation of…
Abstract Number: 786 • 2012 ACR/ARHP Annual Meeting
Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma
Elizabeth E. Gerber¹, Fredrick M. Wigley², Elaine C. Davis³, David L. Huso⁴ and Harry C. Dietz¹, ¹Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Anatomy and Cell Biology, McGill University, Montreal, QC, Canada, ⁴Comparative Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma, defined as pathologic fibrosis of the skin, has many clinical presentations. In the most commonly recognized form, systemic sclerosis (SSc), previously healthy individuals…
Abstract Number: 48 • 2012 ACR/ARHP Annual Meeting
Tissue Engineering for Articular Cartilage Repair, Culturing Bone Marrow Mesenchymal Stem Cells On Collagen and Heparan Sulphate Scaffolds
Adela Helvia Martinez-Sanchez¹, Clara Sanjurjo-Rodriguez¹, Silvia Diaz-Prado², Emma Muiños¹, Isaac M. Fuentes², Francisco J. De Toro², Julia Bujan³ and Francisco J. Blanco¹, ¹Osteoarticular and Aging Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-Complejo Hosp. Univ. A Coruña, A Coruña, Spain, ²Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC-University of A Coruña, A Coruña, Spain, ³Department of Medical Specialties. University of Alcala de Henares, Madrid, Spain
Background/Purpose: The aim of this study was to evaluate the chondrogenic potential of bone marrow mesenchymal stem cells (BM-MSCs) grown on type I collagen and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].